IT stock jumps 5% after board approves increase in buyback price
Aurobindo Pharma (NSE:ARBN) Limited has taken a significant step toward strengthening its international operations with the incorporation of a new wholly owned subsidiary in the United States. Its US arm, Aurobindo Pharma USA Inc., has officially set up Cresedemo Pharma LLC as of June 13, 2025.
The newly formed entity has been established with an initial share capital of USD 10,000, comprising 10,000 shares of USD 1 each. As the company has just been incorporated, there are no revenues to report yet. However, the core objective behind the launch of Cresedemo Pharma LLC is clear: to expand Aurobindo’s pharmaceutical business footprint in the US market. No governmental or regulatory approvals were required for the formation of this subsidiary.
This move marks another calculated step in Aurobindo Pharma’s strategic roadmap to deepen its presence in regulated markets, especially the United States, which continues to be one of its largest revenue contributors. The company’s consistent focus on product pipeline expansion, compliance, and operational scale underpins its global ambitions.
Image Source: InvestingPro
For investors evaluating the company’s prospects, one crucial piece of the puzzle is its current valuation. According to InvestingPro’s Fair Value feature, Aurobindo Pharma is currently undervalued. The fair value of the stock stands at INR 1,334.6, which indicates a potential upside of 16.9% from its current market price of INR 1,150.2. This fair value is derived using a combination of robust financial models and historical data to offer a reliable and realistic picture of the stock’s intrinsic worth.
While market movements can often be driven by sentiment or momentum, true long-term investing success is built on identifying fundamental value. That’s where InvestingPro becomes invaluable. Its fair value estimates help simplify complex valuation analysis, allowing investors to make informed decisions without needing to manually crunch numbers.
For those looking to level up their investing game, InvestingPro is currently running a promotional offer with discounts of up to 45% on its subscription plans. Whether you’re a retail investor or a seasoned trader, having data-backed valuation tools at your fingertips can be a game-changer in today’s market environment.
As Aurobindo Pharma charts new territory in the US, investors now have the tools to assess its growth story with greater clarity and confidence.
Read More: Peek Into Portfolios Worth Billions: The Power of ‘Ideas’ on InvestingPro
X (formerly, Twitter) - Aayush Khanna
LinkedIn - Aayush Khanna